Can bumetanide be a miraculous medicine for autism spectrum disorder: Meta-analysis evidence from randomized controlled trials / Han ZHU ; Jia-Qi JING ; Si-Jia JIA ; Su-Hong YU ; Chang-Jiang YANG in Research in Autism Spectrum Disorders, 114 (June 2024)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 114 (June 2024) . - p.102363 Titre : Can bumetanide be a miraculous medicine for autism spectrum disorder: Meta-analysis evidence from randomized controlled trials Type de document : texte imprimé Auteurs : Han ZHU, Auteur ; Jia-Qi JING, Auteur ; Si-Jia JIA, Auteur ; Su-Hong YU, Auteur ; Chang-Jiang YANG, Auteur Année de publication : 2024 Article en page(s) : p.102363 Langues : Anglais (eng) Mots-clés : Bumetanide  Autism spectrum disorder  Overall core symptoms  Meta-analysis  Randomized controlled trials Index. décimale : PER Périodiques Résumé : Background The efficacy of bumetanide on autism spectrum disorders (ASD) has been extensively studied, but the results remain inconclusive, necessitating a critical examination to determine its therapeutic role. Therefore, this study conducted a meta-analysis of bumetanide treatments for ASD to explore its efficacy and identify subpopulation that responded positively. Methods A systematic search was conducted on PubMed, EMBASE, MEDLINE, PsyclNFO, Web of Science, Clinical Trials.gov, and references in reviews from the earliest available date to September 2023. Randomized controlled trials (RCTs) were identified that evaluated the efficacy of bumetanide in improving overall core symptoms (OCS) of ASD. Therefore, nine studies with 1036 participants were included in the study. Results Bumetanide showed significant effects on OCS of ASD (WMD = ? 1.91, p = 0.006), particularly in sub-domains including relation to inanimate objects, adaption to environment changes, auditory response, near sensory responses, anxiety and hyperactivity. Moderating analysis indicated that a significant effect size of bumetanide on OCS of ASD was observed in specific subgroup, including 3-6 years old (WMD = 1.08, p = 0.008), the tablet (WMD = 2.80, p = 0.003), 3-month intervention (WMD = 2.54, p = 0.003), and the single-center studies (WMD = 2.80, p = 0.003). Conclusions Bumetanide has a large and significant impact on the OCS of ASD. Given the limited number and quality of included RCTs, future research should prioritize conducting large-scale trials focusing on sub-parameters or specific clinical features to comprehensively evaluate the efficacy of bumetanide in subpopulations of children with ASD. En ligne : https://doi.org/10.1016/j.rasd.2024.102363 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=529 [article] Can bumetanide be a miraculous medicine for autism spectrum disorder: Meta-analysis evidence from randomized controlled trials [texte imprimé] / Han ZHU, Auteur ; Jia-Qi JING, Auteur ; Si-Jia JIA, Auteur ; Su-Hong YU, Auteur ; Chang-Jiang YANG, Auteur . - 2024 . - p.102363. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 114 (June 2024) . - p.102363 Mots-clés : Bumetanide  Autism spectrum disorder  Overall core symptoms  Meta-analysis  Randomized controlled trials Index. décimale : PER Périodiques Résumé : Background The efficacy of bumetanide on autism spectrum disorders (ASD) has been extensively studied, but the results remain inconclusive, necessitating a critical examination to determine its therapeutic role. Therefore, this study conducted a meta-analysis of bumetanide treatments for ASD to explore its efficacy and identify subpopulation that responded positively. Methods A systematic search was conducted on PubMed, EMBASE, MEDLINE, PsyclNFO, Web of Science, Clinical Trials.gov, and references in reviews from the earliest available date to September 2023. Randomized controlled trials (RCTs) were identified that evaluated the efficacy of bumetanide in improving overall core symptoms (OCS) of ASD. Therefore, nine studies with 1036 participants were included in the study. Results Bumetanide showed significant effects on OCS of ASD (WMD = ? 1.91, p = 0.006), particularly in sub-domains including relation to inanimate objects, adaption to environment changes, auditory response, near sensory responses, anxiety and hyperactivity. Moderating analysis indicated that a significant effect size of bumetanide on OCS of ASD was observed in specific subgroup, including 3-6 years old (WMD = 1.08, p = 0.008), the tablet (WMD = 2.80, p = 0.003), 3-month intervention (WMD = 2.54, p = 0.003), and the single-center studies (WMD = 2.80, p = 0.003). Conclusions Bumetanide has a large and significant impact on the OCS of ASD. Given the limited number and quality of included RCTs, future research should prioritize conducting large-scale trials focusing on sub-parameters or specific clinical features to comprehensively evaluate the efficacy of bumetanide in subpopulations of children with ASD. En ligne : https://doi.org/10.1016/j.rasd.2024.102363 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=529

Can technology-based interventions be an alternative method for emotion recognition in autism spectrum disorder: Three-level meta-analysis insights from RCTs / Hong-Li XIAO in Research in Autism, 133 (May 2026)  

Public ISBD [article]  inResearch in Autism > 133 (May 2026) . - p.202905 Titre : Can technology-based interventions be an alternative method for emotion recognition in autism spectrum disorder: Three-level meta-analysis insights from RCTs Type de document : texte imprimé Auteurs : Hong-Li XIAO, Auteur ; Han ZHU, Auteur ; Zi-Yao LIU, Auteur ; Tong-Ao ZENG, Auteur ; Jing-Yuan WANG, Auteur ; Saifeina SHATAER, Auteur ; He-Ping WANG, Auteur ; Chang-Jiang YANG, Auteur Article en page(s) : p.202905 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Technology-based interventions  Emotion recognition  Randomized controlled trials  Three-level meta-analysis Index. décimale : PER Périodiques Résumé : Background Technology-based interventions (TBIs) have shown promise for improving emotion recognition (ER) in individuals with autism spectrum disorder (ASD). but the durability of effects and the role of technological features remain unclear. This meta-analysis examined short-term and maintenance outcomes and tested age, technological interactivity, and their interaction as moderators. Methods A systematic literature search of PubMed, MEDLINE, APA PsycINFO, ERIC, IEEE Xplore, and Web of Science was performed from database inception to May 31, 2024. Randomized controlled trials (RCTs) evaluating TBIs for ER in individuals with ASD were included. Twenty-two studies with 893 participants met the inclusion criteria. Effect sizes (Hedges’ g) were pooled using a three-level meta-analytic model. Results TBIs were associated with a moderate short-term improvement in ER (g = 0.68), whereas the follow-up effect was smaller but not robust (g = 0.35). Moderator analyses did not identify statistically significant effects of age, technological interactivity, or their interaction. Statistically significant effects were observed in younger children (3 – 6 years: g = 1.17; 7 – 12 years: g = 0.63), and in lower-interactivity interventions (low: g = 0.93; moderate: g = 0.69). Conclusions TBIs may yield short-term improvements in ER in individuals with ASD, but evidence for sustained effects remains limited. Age, technological interactivity, and their interaction were not robust moderators, despite descriptively larger effects in younger children and lower-interactivity interventions. Given the substantial heterogeneity and uneven sample distribution, larger and more balanced studies are needed to confirm effect durability and identify reliable moderators. En ligne : https://doi.org/10.1016/j.reia.2026.202905 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=585 [article] Can technology-based interventions be an alternative method for emotion recognition in autism spectrum disorder: Three-level meta-analysis insights from RCTs [texte imprimé] / Hong-Li XIAO, Auteur ; Han ZHU, Auteur ; Zi-Yao LIU, Auteur ; Tong-Ao ZENG, Auteur ; Jing-Yuan WANG, Auteur ; Saifeina SHATAER, Auteur ; He-Ping WANG, Auteur ; Chang-Jiang YANG, Auteur . - p.202905. Langues : Anglais (eng) in Research in Autism > 133 (May 2026) . - p.202905 Mots-clés : Autism spectrum disorder  Technology-based interventions  Emotion recognition  Randomized controlled trials  Three-level meta-analysis Index. décimale : PER Périodiques Résumé : Background Technology-based interventions (TBIs) have shown promise for improving emotion recognition (ER) in individuals with autism spectrum disorder (ASD). but the durability of effects and the role of technological features remain unclear. This meta-analysis examined short-term and maintenance outcomes and tested age, technological interactivity, and their interaction as moderators. Methods A systematic literature search of PubMed, MEDLINE, APA PsycINFO, ERIC, IEEE Xplore, and Web of Science was performed from database inception to May 31, 2024. Randomized controlled trials (RCTs) evaluating TBIs for ER in individuals with ASD were included. Twenty-two studies with 893 participants met the inclusion criteria. Effect sizes (Hedges’ g) were pooled using a three-level meta-analytic model. Results TBIs were associated with a moderate short-term improvement in ER (g = 0.68), whereas the follow-up effect was smaller but not robust (g = 0.35). Moderator analyses did not identify statistically significant effects of age, technological interactivity, or their interaction. Statistically significant effects were observed in younger children (3 – 6 years: g = 1.17; 7 – 12 years: g = 0.63), and in lower-interactivity interventions (low: g = 0.93; moderate: g = 0.69). Conclusions TBIs may yield short-term improvements in ER in individuals with ASD, but evidence for sustained effects remains limited. Age, technological interactivity, and their interaction were not robust moderators, despite descriptively larger effects in younger children and lower-interactivity interventions. Given the substantial heterogeneity and uneven sample distribution, larger and more balanced studies are needed to confirm effect durability and identify reliable moderators. En ligne : https://doi.org/10.1016/j.reia.2026.202905 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=585

---

1 (1 - 2 / 2) Par page : 25 50 100 200